ArticleBMC cancer2026
Cancer-control outcomes of patients with metastatic hormone-sensitive prostate cancer and ≥ 10 bone metastases receiving apalutamide: a real-world cohort.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cancer-Control Outcomes of Japanese Vs. German Metastatic Hormone-Sensitive Prostate Cancer Patients: A Real-World Cross-Country Comparison of Patients Undergoing Combination Therapies.International journal of urology : official journal of the Japanese Urological Association · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeCurrently available post-hoc TITAN study data indicate favorable cancer-control in metastatic hormone-sensitive prostate cancer (mHSPC) patients treated with apalutamide, even in patients with high metastatic burden, such as ≥ 10 bone metastases. However, these findings have never been validated in real-world setting. PATIENTS AND
methodsWe relied on the FRAMCAP (FRAnkfurt Metastatic Cancer database of the Prostate) and stratified apalutamide-treated mHSPC patients according to number of bone metastases (≥ 10 vs. < 10). Primary endpoints were time to metastatic castration-resistant prostate cancer (ttCRPC) and overall survival (OS). Finally, exploratory analyses were made against mHSPC treatment with abiraterone and docetaxel.
resultsOf 105 apalutamide-treated mHSPC patients, median age was 71 years and median PSA 46 ng/ml. In total, 23% of included patients had ≥ 10 bone metastases. Patients with ≥ 10 bone metastases harbored higher PSA level at treatment start (254 vs. 29 ng/ml) and achieved less PSA response under treatment (PSA nadir 0.64 vs. 0.03 ng/ml, both p < 0.01). Regarding ttCRPC, no statistically significant difference was observed between ≥ 10 vs. < 10 bone metastases with median ttCRPC of 32 vs. 37 months (p = 0.15). Regarding OS, median OS was significantly shorter for ≥ 10 vs. < 10 bone metastases (29 vs. 64 months, hazard ratio: 2.5, p = 0.02), even after multivariable adjustment for baseline patient and tumor characteristics. In further analyses, apalutamide (32 months) showed numerically longer median ttCRPC compared to abiraterone (18 months) and docetaxel (16 months) in patients with ≥ 10 bone metastases.
conclusionIn real-world setting, apalutamide-treated mHSPC patients presenting with a high bone metastatic burden achieve virtually similar ttCRPC outcomes compared to those with a lower metastatic burden. Exploratory comparisons with other first-line doublet mHSPC treatment options indicate a potential advantage of apalutamide. CLINICAL
trial registrationNot applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.